Barbara Ann Karmanos Cancer Institute
karmanos.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
157
Active
21
Phase 3
2
Total enrollment
8,000
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Gemcitabine | — | — | — | — | — | 4 | |
| Prednisone | — | — | — | — | 4 | ||
| rituximab | — | — | — | — | — | 3 | |
| doxorubicin hydrochloride | — | — | — | — | — | 2 | |
| Selinexor | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Fruquintinib | — | — | — | — | — | 1 | |
| Iberdomide | — | — | — | — | — | 1 | |
| Daratumumab/rHuPH20 Co-formulation | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Polatuzumab Vedotin | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 1 | |
| cyclophosphamide | — | — | — | — | 9 | ||
| 1-(2-[18F]FLUOROETHYL)-L-Tryptophan | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 1 |
Next readouts
- 2025-06-19
- 2027-04
- 2027-07
- 2027-07-07
- 2027-12
- 2027-12-31
- 2027-12-31
- 2028-04-17
Top conditions
- Lung Cancer15
- Breast Cancer15
- Prostate Cancer13
- Multiple Myeloma and Plasma Cell Neoplasm12
- Unspecified Adult Solid Tumor, Protocol Specific10
- Leukemia10
- Lymphoma10
- Myelodysplastic Syndromes8
Frequently asked questions about Barbara Ann Karmanos Cancer Institute
- How many clinical trials does Barbara Ann Karmanos Cancer Institute have on ClinicalTrials.gov?
- Barbara Ann Karmanos Cancer Institute is listed as the lead sponsor on 157 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Barbara Ann Karmanos Cancer Institute's trials are in Phase 3?
- 2 of Barbara Ann Karmanos Cancer Institute's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Barbara Ann Karmanos Cancer Institute focus on?
- Barbara Ann Karmanos Cancer Institute's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Breast Cancer, Prostate Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific.
- When are Barbara Ann Karmanos Cancer Institute's next clinical trial readouts?
- Barbara Ann Karmanos Cancer Institute has 8 upcoming primary-completion readouts tracked here; the soonest is “Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma”, expected around 2025-06-19.